

1 **Sex differences in innate anti-viral immune responses to respiratory** 2 **viruses**

3

4 Eteri Regis^{1#}, Sara Fontanella^{1#}, Lijing Lin², Rebecca Howard², Sadia Haider¹, John A. Curtin³, Michael R.
5 Edwards¹, Magnus Rattray², Angela Simpson³, Adnan Custovic^{1†}, Sebastian L. Johnston^{1*†}

6

7 ¹National Heart and Lung Institute, Imperial College London, United Kingdom

8 ²Faculty of Biology, Medicine and Health, University of Manchester, M13 9PT, UK

9 ³Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health,

10 Manchester Academic Health Sciences Centre, University of Manchester and University Hospital of South

11 Manchester NHS Foundation Trust, Manchester, UK

12

13 *To whom correspondence should be addressed: Sebastian L Johnston, Professor of Respiratory

14 Medicine & Allergy, National Heart and Lung Institute, Imperial College London, Norfolk Place, London

15 W2 1PG, United Kingdom; Tel: +44 20 7594 3764, e-mail: s.johnston@imperial.ac.uk

16

17 **Classification:** Biological sciences; Immunology and Inflammation.

18 **Key words:** mortality, respiratory virus, COVID-19, gender, innate immunity, interferons

19

20 **Author Contributions:**

21 [#]Eteri Regis and Sara Fontanella contributed equally to this article

22 [†]Adnan Custovic and Sebastian Johnston contributed equally to this article

23

24

25 **Abstract**

26 Males have excess morbidity and mortality from respiratory viral infections and especially so in COVID-
27 19. The mechanisms explaining this excess in disease burden in males are unknown. Innate immune
28 responses are likely critical in protection against a novel virus like SARS-CoV-2. We hypothesised that
29 innate immune responses may be deficient in males relative to females. To test this we stimulated
30 peripheral blood mononuclear cells (PBMCs) from participants in a population-based birth cohort with
31 three respiratory viruses (rhinoviruses-RV-A16 and RV-A1, and respiratory syncytial virus-RSV) and two
32 viral mimics (R848 and CpG-A, to mimic responses to SARS-CoV-2). We measured interferon (IFN) and
33 IFN-induced chemokine responses and investigated sex differences in virus-induced responses. IFN- α ,
34 IFN- β and IFN- γ responses to RV-A16 were deficient in males compared to females, fold-inductions being
35 1.92-fold ($P<0.001$), 2.04-fold ($P<0.001$) and 1.77-fold ($P=0.003$) lower in males than females,
36 respectively. Similar significant deficiencies in innate immune responses were observed in males for
37 eleven other cytokine-stimulus pairs. Responses in males were greater than those in females in only one
38 of 35 cytokine-stimulus pairs investigated. Review of healthcare records revealed that 12.1% of males but
39 only 6.6% of females were admitted to hospital with respiratory infections in the first year of life ($P=0.017$).
40 Impaired innate anti-viral immunity in males likely results in high morbidity and mortality from respiratory
41 viruses including COVID-19. Males may preferentially benefit from therapies that boost innate anti-viral
42 immune responses.

43

44 **Significance Statement**

45 Clinical outcomes including, mortality, Intensive care unit admissions and hospital admissions, during
46 COVID-19 disease are consistently and substantially worse in males than in females. The mechanisms
47 underlying this increased susceptibility to severe disease in males are not understood. We hypothesised
48 that the differential outcomes between sexes could be a consequence of deficient innate interferon
49 responses in males, and more robust innate interferon responses in females. We have investigated such
50 responses in a large population-based cohort and found that indeed males have deficient innate interferon
51 responses to viral stimuli, including stimuli that mimic SARS-CoV-2 infection, relative to females. Our
52 findings have very important treatment implications as interferons are available for clinical use with
53 immediate effect.

54

55 **Introduction**

56 Respiratory viral infections are a leading cause of ill health and mortality(1). This has been highlighted by
57 the immense global impact of COVID-19(2) and the enormous public health threat it poses. Males and
58 females differ in the prevalence and severity of viral infections(3). In COVID-19, risk factors for mortality
59 include older age, the presence of comorbid conditions, and male sex(4, 5). In an early report of 191
60 cases from Wuhan, China, 70% of deaths were male, while only 30% were female(5). This gender
61 imbalance has subsequently been confirmed in a large study of 44,672 COVID-19 confirmed cases in
62 China, where 63.8% of deaths were male while only 36.2% were female, and the case fatality rate for
63 males was 2.8%, while that for females was 1.7%(6). Similar mortality data are reported in Italy where
64 9390 of 13,334 (70.4%) of COVID-19 deaths in persons under 90 years of age reported by 6th April 2020
65 were male, and 3,944 (29.6%) were female(7). In the UK, the data are very similar, with males
66 representing 65% of deaths involving COVID-19 reported by 27th March 2020, while 35% were
67 females(8). Intensive Care Unit (ICU) admission are also much higher for males in Lombardy, Italy, where
68 82% of 1591 ICU admissions were male(9). The ICU data are very similar in the UK, as 72.5% of 3883
69 confirmed COVID-19 cases admitted to ICU by the 10th April 2020 were male, and 27.5% female(10). A
70 recent large UK study of 20,133 patients admitted to hospital with COVID-19, reported more men were
71 admitted than women (men 60%, n=12 068; women 40%, n=8065)(11). An even larger study of primary
72 care records of 17,278,392 adults linked to 10,926 COVID-19-related deaths reported COVID-19-related
73 death was associated with: being male with a hazard ratio of 1.59(12). COVID-19 case identification in
74 population screening also reports a male preponderance, with more males than females testing positive
75 in both targeted testing (16.7% vs 11.0%) and in population screening (0.9% vs 0.6%)(13).

76 The mechanisms explaining excess COVID-19 mortality, ICU and hospital admissions and case
77 identification in males are unknown(14). Understanding how sexes differ in their responses to respiratory
78 viruses is critically important for the development of treatment and preventative strategies, which may
79 differ for males and females. Innate immune responses, mediated by anti-viral interferon (IFN) production
80 by virus-infected cells will be critical in protection against SARS-CoV-2, a new virus that humans have
81 never previously encountered. We have previously reported that deficient IFN- α (15), IFN- β (15, 16) and

82 IFN- γ (17, 18) production by virus-infected cells from people with asthma is implicated in their increased
83 susceptibility to respiratory virus infections(19). However, little is known about the variation within the
84 human immune system in relation to the patterns of response to viruses at a population level. We
85 hypothesised that the adverse outcomes for males reported in COVID-19 may be related to deficient
86 innate immune responses to viruses in males relative to females. To investigate this, we stimulated
87 peripheral blood mononuclear cells (PBMCs) from male and female participants in a population-based
88 birth cohort with three common respiratory viruses and two viral mimics (R848 and CpG-A, to mimic
89 responses to SARS-CoV-2) and measured IFN and IFN-induced chemokine responses in supernatants.
90

91 **Results**

92 ***Participant flow and demographic data***

93 Of 751 participants who attended follow-up at age 16 years, 361 provided blood samples. After quality
94 control (Supplementary Appendix), we excluded data for 16 participants. Participant flow is presented in
95 Fig. 1. There were no differences in demographic characteristics, environmental exposures and clinical
96 features between participants included in this analysis (n=345) and those who were not (n=406), either in
97 the whole population or stratified by sex (Table S1).

98 The demographic and clinical characteristics of the 345 subjects included in this analysis are shown in
99 Table 1. There were no significant differences between sexes in birth weight, relevant environmental
100 exposures (including position in sibship, pet ownership and tobacco smoke exposure) or common
101 respiratory diseases, such as wheezing and asthma. No significant differences were observed in cell
102 viability between sexes (Fig. S1).

103 ***Induction of IFNs and IFN-induced chemokines in PBMCs in response to viral stimuli***

104 There was a significant induction of all IFNs and IFN-induced chemokines in response to all viral stimuli
105 compared to medium control (Figures 2 and S2). Cytokine responses to viral stimuli were not normally
106 distributed (Shapiro-Wilk test, Table S2). The most potent inducers of IFN- α were CpG-A, RSV and RV-
107 A16, with median concentrations of 184.7pg/mL, 108.3pg/mL and 34.0pg/mL respectively compared to
108 0.0pg/mL in medium control (all $P<0.001$, Figure 2). RV-A1 and R848 also induced IFN- α , but to lesser
109 degrees (Fig. 2). Induction of IFN- β followed a very similar pattern to that of IFN- α , but with lower
110 concentrations.

111 The most potent inducers of IFN- γ were R848, RV-A16 and RSV, with median concentrations of
112 102.1pg/mL, 60.7pg/mL and 35.7pg/mL, respectively, compared to 0.2pg/mL in medium control (all
113 $P<0.001$, Figure 2). RV-A1 and CpG-A also induced IFN- γ , but to lesser degrees (Fig. 2).

114 The most potent inducers of the IFN-induced chemokine CXCL10/IP-10, were RV-A16, RSV and CpG-A,
115 with median concentrations of 1841.0pg/mL, 1515.2pg/mL and 1343.4pg/mL respectively, compared to

116 130.6pg/mL in medium control samples (all $P < 0.001$, Figure 2). RV-A1 and R848 also induced CXCL-
117 10/IP-10, but to lesser degrees.

118 The IFN-induced chemokines CCL2/MCP1, CCL4/MIP-1 β and CCL13/MCP4 were also all induced by all
119 viral stimuli, CCL2/MCP1 and CCL4/MIP-1 β most potently by R848 and CCL13/MCP4 most potently by
120 RV-A1 (Fig. S2).

121 ***Differences between males and females in IFN and IFN-induced chemokine induction***

122 Results of the comparisons between sexes are presented in Table 2. The trend across all viral stimuli and
123 responses was remarkably consistent, as almost all of the IFNs and IFN-induced chemokines had higher
124 levels of induction in females compared to males: out of 35 stimulus-cytokine pairs, females exhibited
125 higher induction than males in 32 cases (Table 2).

126 The induction of IFN- α was significantly higher in females than in males for all five viral stimuli (with P -
127 values ranging from < 0.001 to 0.018, Table 2). After adjustment for multiple testing, these differences
128 remained statistically significant for RV-A16, RV-A1 and R848 ($P = 0.001$, 0.041 and 0.002 respectively),
129 and marginal for RSV and CpG-A ($P = 0.055$ and 0.051 respectively, Table 2). The magnitude of the
130 differences observed for IFN- α ranged from a 1.34-fold (34%) greater induction of IFN- α in females than
131 in males for RSV, to a 2.06-fold (106%) greater induction for R848.

132 The individual responses of each IFN and of CXCL10/IP-10 to RV-A16 stimulation are depicted in Fig. 3
133 A-D, with induction in females significantly greater than that in males for IFN- α at 1.92-fold (92%) greater
134 ($P < 0.001$), IFN- β at 2.04-fold (104%) greater ($P < 0.001$), IFN- γ 1.77-fold (77%) ($P = 0.003$) and CXCL10/IP-
135 10 1.40-fold (40%) greater ($P = 0.01$).

136 Regarding the viral mimics R848 and CpG-A (which mimic responses to SARS-CoV-2 infection), females
137 had significantly greater induction of IFN- α in response to R848 stimulation (2.06-fold, $P < 0.001$), and in
138 response to CpG-A (1.71-fold, $P = 0.015$) (Fig. 4 A-B), though the latter difference was marginal after
139 adjustment ($P = 0.051$, Table 2). Females also had significantly greater induction of IFN- γ (2.01-fold,
140 $P = 0.003$) and CCL13/MCP4 (1.36-fold, $P = 0.04$) in response to CpG-A than males (Fig. 4 C-D), though
141 the latter difference was marginal after adjustment ($P = 0.10$, Table 2).

142 Stimulation with RV-A1 also resulted in significantly greater induction in females than in males for IFN- α
143 (Fig. S3A, 1.55-fold, $P=0.011$), CXCL10/IP-10 (Figure S3B, 1.23-fold, $P=0.041$, though this difference
144 was marginal after adjustment [$P=0.10$, Table 2]), CCL4/MIP-1 β (Fig. S3C, 1.16-fold, $P=0.01$) and
145 CCL13/MCP4 (Fig. S3D, 1.61-fold, $P=0.002$), as did stimulation with RSV (Fig. S3 E-F) for IFN- α
146 ($P=0.018$) and CCL13/MCP4 ($P=0.019$). These latter two differences were marginal after adjustment
147 (both $P=0.055$, Table 2).

148 Since adverse clinical outcomes in viral infections are likely in those individuals with the weakest innate
149 anti-viral responses, we examined proportions of males and females whose innate anti-viral responses
150 were below certain lower thresholds. We restricted this analysis to IFN- α and low thresholds were defined
151 as the 15th, 20th and 25th percentile of the response determined from the entire population. Results are
152 shown in Fig. 5 and S4. Proportions of males having IFN- α responses to RV-A16, RSV and R848 below
153 each threshold were significantly higher compared to the proportion of females (Fig. 5). Similar trends
154 were observed for response of IFN- α to RV-A1, and CpG-A (Fig. S4), but these did not reach statistical
155 significance.

156 ***Differences in early-life severe LRTIs between males and females***

157 Having observed diminished innate immune responses to viral stimuli in males, and greater proportions of
158 males with weak innate immune responses, we investigated whether frequencies of early-life LRTIs were
159 also different between sexes in our cohort. We focussed on early life, as this is when innate immune
160 responses will be most important, as the very young will have had little opportunity to develop memory
161 responses. Results are presented in Table S3. Among participants attending follow up at age 16 years
162 who had primary care records available for inspection ($n=651$), 12.1% of males and 6.6% of females were
163 admitted to hospital with LRTI in the first year of life ($P=0.017$). In the second year of life, 6.1% of males
164 but only 0.75% of females were admitted to hospital with LRTI ($P < 0.001$). We observed a similar trend
165 for RSV-positive bronchiolitis, with 4.32% of males hospitalised, compared to 1.64% of females, but the
166 difference between the sexes did not reach formal statistical significance ($P=0.067$).

167

168 Discussion

169 We hypothesised that the adverse outcomes for males reported in virus infections and especially in
170 SARS-CoV-2 infections, including substantially increased COVID-19-related mortality, ICU admissions,
171 hospital admissions and case identification, may be related to deficient innate immune responses in
172 males relative to females, resulting in increased disease severity in males. Our analysis of induction of
173 three IFNs and four IFN-induced chemokines by five respiratory viruses/viral stimuli in PBMCs sampled
174 from participants in a population-based birth cohort study demonstrated that responses in females were
175 substantially greater than those in males in 32 of 35 cytokine-stimulus pairs. Of these, differences in 14
176 cytokine-stimulus pairs were statistically significant, of which 9 remained significant after adjustment for
177 multiple testing, all showing increased responses in females. These statistically significant cytokine-
178 stimulus pairs included IFN- α induction in response to each viral stimulus, IFN- β induction in response to
179 RV-A16 and IFN- γ induction in response to RV-A16 and CpG-A.

180 IFN- α and IFN- β are type I IFNs that are critical mediators of innate anti-viral immune responses, inducing
181 apoptosis of virus-infected cells and inducing over 300 IFN-stimulated genes, many of which have a
182 variety of direct anti-viral activities(20). Through these combined activities, type I IFNs can abort virus
183 replication in virus-infected cells(16).

184 IFN- γ is the only type II IFN, and it also is very important in promoting innate immune responses
185 principally by activating natural killer (NK) cells which are important in innate immune defense against
186 virus infections, by rapid killing of virus-infected cells(21). IFN- γ also primes other immune cells such as
187 macrophages, to release anti-viral cytokines(22) and to phagocytose infected cells(21). IFN- γ has been
188 shown to suppress mouse coronavirus replication, though this was dependent, in part, on induction of
189 type I IFN secretion(23).

190 Type I and II IFNs also cooperate and work together to activate macrophages, NK cells, dendritic cells
191 and T cells by enhancing cell activation, antigen presentation, cell trafficking, cell differentiation and
192 proliferation, resulting in markedly enhanced innate and acquired antiviral immune effector function(24).
193 Thus, deficiency in either or both of these IFN types would be expected to markedly increase severity of
194 virus-induced illnesses. We have previously described deficiency in IFN- α (15), IFN- β (15, 16) and IFN-

195 γ (17, 18) in patients with asthma and have reported that patients with asthma have increased
196 susceptibility to respiratory virus infections(19). In addition, recent reports indicate that deficiencies in IFN
197 responses are linked to increased susceptibility to virus-induced exacerbations of chronic obstructive
198 pulmonary disease(25-28). These data therefore support the biological and clinical relevance of our
199 findings.

200 The deficiencies we observed in IFN responses in males are reflected in a significantly increased
201 incidence of severe LRTIs requiring hospital admissions in the first and second years of life, as well as
202 with a trend for increased incidence of RSV-proven bronchiolitis, a disease with a peak incidence at 4.5
203 months of age(29). We focused on severe LRTIs requiring hospital admissions in early life, as these are
204 almost exclusively viral in aetiology. The first 2 years of life is a time of life during which innate immune
205 responses will be most important, as infants and toddlers will have had very little experience of viral RTIs
206 and will therefore have little memory/acquired immunity. The fact that we find females produce
207 approximately twice the concentrations of IFN- α and IFN- β in response to RV-A16 and of IFN- α in
208 response to R848, 55% more IFN- α in response to RV-A1 and 71% and 52% more IFN- α and IFN- β in
209 response to CpG-A, than do males, and females have ~half the number of LRTIs requiring hospital
210 admission in the first year of life, 88% fewer in the second year of life and 62% fewer admissions with
211 RSV-positive bronchiolitis also lends credence to the biological and clinical relevance of our findings in
212 relation to diseases where innate immune responses will be vitally important in protection against adverse
213 outcomes.

214 SARS-CoV-2 is a virus completely new to mankind, it is therefore even more important to have as strong
215 an innate immune response to this virus as possible, to reduce the likelihood of adverse outcomes. The
216 marked reductions in type I IFN responses to viral stimuli reported herein in males relative to females,
217 with the relationships discussed above with virus-induced exacerbations of lung disease(15-18, 25-28),
218 and with severe viral LRTIs in infants in our cohort, make it almost certain that the deficient IFN
219 responses we report in males will be at least in part responsible for the adverse outcomes to SARS-CoV-
220 2 infection currently being reported in COVID-19 in males(2, 4-10, 12, 13).

221 A very recent study by Takahashi et al studied sex differences in immune responses during COVID-19
222 disease in hospitalised patients and claimed that these differences underlie sex differences in COVID-19
223 disease outcomes(30). This study reported female patients mounted significantly more robust T cell
224 activation than male patients during SARS-CoV-2 infection. They also found that a poor T cell response
225 was associated with worse disease outcome in male patients. This study also reported significantly
226 increased plasma concentrations of IL-8 and IL-18 and numbers of peripheral blood non-classical
227 monocytes in males, with trends to increased SARS-CoV-2 virus load (of magnitude 1-2 Log₁₀ copies/mL,
228 noting that virus load was only measured in the upper respiratory tract and not in the lung) and plasma
229 CXCL-10 concentrations in males. As robust innate interferon responses are well known to drive robust T
230 cell responses during viral infections(24), and deficient innate interferon responses studied *ex vivo* pre-
231 infection are known to relate to increased virus load, increased inflammatory outcomes and worse clinical
232 outcomes upon subsequent *in vivo* respiratory virus infection(31), we suggest all the differential outcomes
233 between sexes identified by Takahashi et al would be a consequence of the deficient innate interferon
234 responses in males, and more robust innate interferon responses in females, that we report herein.

235 Our study has strengths and limitations. Strengths include the population-based cohort design, so our
236 participants should be representative of the general population, the fact that illness ascertainment was
237 carried out by personal inspection of primary care records to maximise accuracy, that PBMCs were
238 stimulated/infected with the most common respiratory viruses and with ligands of TLRs that are
239 representative of RNA respiratory viruses such as SARS-CoV-2, and that infections/stimulations were
240 carried out using a single batch of each virus/stimulus and conducted by a single highly experienced
241 individual, so any variability in response will be participant-related and not a result of technical variability.
242 Limitations include that PBMCs were not directly infected/stimulated with SARS-CoV-2. This was not
243 possible as our participants' PBMCs were infected/stimulated before SARS-CoV-2 existed as a human
244 pathogen. However, we did study ligands (R848 and CpG-A) to the endosomal expressed TLRs 7/8/9,
245 which are clearly engaged by positive strand RNA viruses such SARS-CoV-2, which require endosomal
246 processing as part of viral entry into cells(32). Furthermore, consistency of findings across all viral stimuli
247 and responses suggests that our findings should apply to all respiratory viruses including SARS-CoV-2.

248 We were not able to assess the importance of induction of the type III IFNs, IFN- λ s 1-3, which are very
249 important in innate antiviral responses against respiratory viruses(31, 33-35), as the type III IFNs were not
250 significantly induced by any infection/stimulus in the PBMCs that we studied (data available on request).
251 This is likely because respiratory epithelial cells are the main source of type III IFNs, and the cells within
252 PBMCs that are capable of producing type III IFNs when studied fresh(35) likely succumbed as a result of
253 freeze/thawing.

254 Our findings have important therapeutic implications. IFN- α and IFN- β have both been shown to inhibit
255 replication of SARS-CoV-2(36, 37). A very recent report indicates that early subcutaneous IFN- β
256 administered up to three times weekly (with ribavirin) in the first seven days after diagnosis of COVID-19
257 was associated with faster virus clearance and clinical improvement and with shorter hospital stays(38). It
258 is likely that most of this clinical benefit resulted from IFN- β rather than ribavirin(39), but ongoing clinical
259 trials (more than 20 trials investigating IFN- α or IFN- β in COVID-19 are currently registered on clinical trial
260 registries) will determine whether and to what degree type I IFN therapies are effective.

261 Since IFN production by virus-infected respiratory cells is likely critical to innate anti-viral immunity against
262 SARS-CoV, therapeutic use of agents that boost innate IFN induction by virus infections may be
263 efficacious in treatment of COVID-19. We reported 10 years ago that azithromycin doubles IFN- β and
264 IFN- λ production from virus-infected human bronchial epithelial cells *in vitro*(40). Erythromycin and
265 telithromycin did not(40). Innate IFN-induction by azithromycin in virus-infected human lung cells has
266 been confirmed in three subsequent studies(41-43), one of which confirmed this property was variable
267 among 225 novel macrolides studied, as some macrolides induced innate IFNs (up to ~5-fold), while
268 others did not(43). Thus this innate IFN-inducing property is not a property of all macrolides, but is
269 reproducibly a property of azithromycin(40-43). This is supported by a recent report that among 1,520
270 clinically approved compounds from a chemical library screened for anti-viral activity against SARS-CoV-
271 2, only two had clear dose-responsive replication-inhibition curves with identified EC₅₀ concentrations in
272 the 1-10 μ M range. These two compounds were azithromycin and hydroxychloroquine, and they also had
273 EC₉₀ concentrations of ~10 μ M and ~15 μ M respectively, with azithromycin achieving ~100% inhibition of
274 SARS-CoV-2 replication at ~15 μ M(44). Azithromycin treatment of COVID-19 patients (especially early in

275 the disease course when patients progress from mild to moderate disease severity) in order to boost IFN
276 production by respiratory epithelial cells when infected with SARS-CoV-2, may therefore be effective,
277 especially in males who demonstrably have deficient innate IFN responses when compared to females.
278 This deduction is indirectly supported by high-quality randomised, double-blind, placebo-controlled clinical
279 trial evidence that azithromycin is effective in preventing progression to severe lower respiratory tract
280 illnesses (which are initiated by viral infections) in preschool children(45) and in prevention of asthma
281 exacerbations (the great majority of which are caused by respiratory viruses) in uncontrolled
282 moderate/severe asthma(46). Ongoing studies (more than 50 clinical trials investigating azithromycin in
283 COVID-19 are currently on trial registries) will determine the effectiveness of azithromycin, and we would
284 suggest that post-hoc analyses include stratification by sex.

285 Our findings have important implications for prevention strategies, which are best implemented when
286 high-risk populations can be identified. Respiratory viruses, including SARS-CoV-2, are initially
287 encountered by the nasal epithelium where infection is initiated. An adequate anti-viral response can
288 contain the virus in the upper airway, with cold-like symptoms, and a diminished response can see the
289 infection spreading to the lower airways to induce severe LRTI. Our data support a preventive strategy,
290 particularly among males, which involves targeting the innate immune system with 'immune training'
291 agents to boost resistance to primary infection with SARS-CoV-2 and enhance the capacity to control the
292 intensity of airways' inflammatory responses (such as, for example, OM-85(47), which has been shown to
293 effectively and safely reduce winter hospitalizations in COPD(48), severe bronchitis among residents in
294 care-homes for elderly(49), and LRTIs in children(50)). Effective prophylactic therapy will be crucially
295 important while we wait for a vaccine.

296 Our findings also have important implications for a hotly debated topic, namely whether "man flu" actually
297 exists or not(51). Here we provide a biological basis to explain why males would be expected to suffer
298 more than females when infected by respiratory viruses.

299 In conclusion, high morbidity and mortality from respiratory viruses including COVID-19 in males is likely
300 explained by impaired innate anti-viral immune in males compared to females. Males may preferentially

301 benefit from therapies that boost innate anti-viral immune responses to viruses, both for treatment and
302 prevention.

303 **Materials and Methods**

304 Detailed methods are presented in the Supplementary Appendix.

305 ***Study design, setting, participants and data sources***

306 The study subjects were participants in the Manchester Asthma and Allergy Study, a population-based
307 birth cohort study(52). The study was approved by the research ethics committee; we obtained written
308 informed consent. PBMCs were collected from subjects at age 16 years and cryopreserved. We used
309 male or female sex as assigned at birth.

310 ***Cell stimulations and cytokine measurement***

311 The PBMCs were thawed on the day of stimulation, counted and had viability checked as described(53,
312 54). Cells were distributed in 96-well round bottom plates at 2×10^5 cells/well and were stimulated with two
313 rhinoviruses (RVs), RV-A16 and RV-A1, and respiratory syncytial virus (RSV). We also used two viral
314 mimics (which mimic infection with SARS-CoV-2), the Toll-like receptor (TLR)-7/8 ligand resiquimod
315 (R848) and the TLR-9 ligand class A CpG oligonucleotide (CpG-A), both at $1 \mu\text{M}$ concentrations
316 (Invivogen). Concentrations of IFN- α , IFN- β , IFN- γ and four IFN-induced chemokines CXCL10/IP-10,
317 CCL2/MCP1, CCL4/MIP-1 β and CCL13/MCP4 were measured in supernatants 24h post-stimulation,
318 using the Meso Scale Discovery® kits as previously described(53, 54).

319 ***Clinical outcomes: Lower respiratory tract infections (LRTI)***

320 We extracted data on severe LRTIs requiring hospital admissions in the first and second year of life from
321 electronic and paper-based primary care medical records; age in days at the time of each event was
322 documented to provide an accurate account of each episode(54).

323 ***Statistical analysis***

324 *Quality control:* Prior to analyses, data were pre-processed according to the pipeline described in our
325 previous study(53), to exclude samples with low viability and/or no response of any cytokine to any stimulus.

326 *Analysis:* We expressed the induction of IFNs and IFN-induced chemokines as raw values (in pg/mL) and
327 fold-induction over medium controls. The data were summarised as median and interquartile range (IQR).

328 Univariate comparisons between groups were performed using the Wilcoxon rank sum test (2-tailed).
329 Benjamini-Hochberg correction was applied to account for multiple testing(55). Proportions of males and
330 females with IFN responses to viral stimuli below the 15th, 20th and 25th percentiles of the entire
331 population were compared using chi-squared tests. Associations with $P<0.05$ were considered significant.

332 ***Data availability***

333 The data that support the findings of this study are available from the corresponding author upon
334 reasonable request.

335

336 **Acknowledgments:**

337 **Funding:** MRC grants MR/L012693/1, MR/K002449/2 and MR/S025340/1. SLJ is the Asthma UK Clinical
338 Chair (grant CH11SJ) and a National Institute of Health Research (NIHR) Emeritus Senior Investigator
339 and is funded in part by European Research Council Advanced Grant 788575. This research was
340 supported by the NIHR Imperial and Manchester Biomedical Research Centres (BRCs). The views
341 expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health
342 and Social Care.

343 **Author contributions:** All authors contributed to the writing of the manuscript and have approved the
344 final version for publication. E.R., S.F., L.L., R.H., J.C., M.R. and M.E. performed the data analyses and
345 E.R., S.F., graph and table production. E.R. performed all cell infections/stimulations and all cytokine
346 measurements. S.H. performed primary care record inspection. A.S. coordinated the clinical study, A.C.
347 and S.J. lead the study design, supervision and interpretation of the studies.
348 A.S., A.C. and S.J. are responsible for the overall content as guarantors. The guarantors accept full
349 responsibility for the work, the conduct of the study, had access to the data, and controlled the decision to
350 publish. The corresponding author attests that all listed authors meet authorship criteria and that no
351 others meeting the criteria have been omitted.

352 **Competing interests:** Dr. Johnston reports personal fees from Virtus Respiratory Research, personal
353 fees from Myelo Therapeutics GmbH, personal fees from Concert Pharmaceuticals, personal fees from
354 Bayer, personal fees from Synairgen, personal fees from Novartis, personal fees from Boehringer
355 Ingelheim, personal fees from Chiesi, personal fees from Gerson Lehrman Group, personal fees from
356 resTORbio, personal fees from Bioforce, personal fees from Materia Medical Holdings, personal fees from
357 PrepBio Pharma, personal fees from Pulmotect, personal fees from Virion Health, personal fees from
358 Lallemand Pharma, personal fees from AstraZeneca, outside the submitted work; In addition, Dr.
359 Johnston has a patent Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory
360 diseases. UK patent application No. GB 0405634.7, 12 March 2004. with royalties paid, a patent Wark
361 PA, Johnston SL, Holgate ST, Davies DE. Interferon-Beta for Anti-Virus Therapy for Respiratory
362 Diseases. International Patent Application No. PCT/GB05/50031, 12 March 2004. with royalties paid, and

363 a patent Davies DE, Wark PA, Holgate ST, Johnston SL. Interferon Lambda therapy for the treatment of
364 respiratory disease. UK patent application No.6779645.9, granted 15th August 2012. licensed.
365 Dr. Custovic reports personal fees from Novartis, personal fees from Thermo Fisher Scientific, personal
366 fees from Philips, personal fees from Sanofi, personal fees from Stallergenes Greer, outside the
367 submitted work.
368 Dr. Simpson reports grants from MRC, grants from NIHR BRC, during the conduct of the study.
369 Dr. Curtin reports a patent with the University of California at San Francisco, unrelated to the submitted
370 work.
371 The rest of the authors declare that they have no relevant conflicts of interest.

372 **References**


- 373 1. J. P. Mizgerd, Lung infection--a public health priority. *PLoS Med* **3**, e76 (2006).
- 374 2. F. Wu *et al.*, A new coronavirus associated with human respiratory disease in China. *Nature* **579**,
375 265-269 (2020).
- 376 3. S. L. Klein, Sex influences immune responses to viruses, and efficacy of prophylaxis and
377 treatments for viral diseases. *Bioessays* **34**, 1050-1059 (2012).
- 378 4. X. Li *et al.*, Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J*
379 *Allergy Clin Immunol* 10.1016/j.jaci.2020.04.006 (2020).
- 380 5. F. Zhou *et al.*, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in
381 Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054-1062 (2020).
- 382 6. T. Novel Coronavirus Pneumonia Emergency Response Epidemiology, [The epidemiological
383 characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China].
384 *Zhonghua Liu Xing Bing Xue Za Zhi* **41**, 145-151 (2020).
- 385 7. L. e. p. l. s. p. l. S. d. Sanità., Characteristics of COVID-19 patients dying in Italy. Report based on
386 available data on April 6th , 2020.
- 387 8. O. o. N. Statistics, The number of deaths involving COVID-19 for females was lower than males in
388 all age groups. (2020).
- 389 9. G. Grasselli *et al.*, Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-
390 CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA* 10.1001/jama.2020.5394 (2020).
- 391 10. I. c. n. a. r. c. (ICNARC), ICNARC report on COVID-19 in critical care 10 April 2020. 5 (2020).
- 392 11. A. B. Docherty *et al.*, Features of 20 133 UK patients in hospital with covid-19 using the ISARIC
393 WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* **369**,
394 m1985 (2020).
- 395 12. E. J. Williamson *et al.*, Factors associated with COVID-19-related death using OpenSAFELY.
396 *Nature* **584**, 430-436 (2020).
- 397 13. D. F. Gudbjartsson *et al.*, Spread of SARS-CoV-2 in the Icelandic Population. *N Engl J Med*
398 10.1056/NEJMoa2006100 (2020).
- 399 14. C. Wenham, J. Smith, R. Morgan, Gender, C.-W. Group, COVID-19: the gendered impacts of the
400 outbreak. *Lancet* **395**, 846-848 (2020).
- 401 15. A. Sykes *et al.*, Rhinovirus 16-induced IFN-alpha and IFN-beta are deficient in bronchoalveolar
402 lavage cells in asthmatic patients. *J Allergy Clin Immunol* **129**, 1506-1514 e1506 (2012).
- 403 16. P. A. Wark *et al.*, Asthmatic bronchial epithelial cells have a deficient innate immune response to
404 infection with rhinovirus. *J Exp Med* **201**, 937-947 (2005).
- 405 17. S. D. Message *et al.*, Rhinovirus-induced lower respiratory illness is increased in asthma and
406 related to virus load and Th1/2 cytokine and IL-10 production. *Proc Natl Acad Sci U S A* **105**,
407 13562-13567 (2008).
- 408 18. N. G. Papadopoulos, L. A. Stanciu, A. Papi, S. T. Holgate, S. L. Johnston, A defective type 1
409 response to rhinovirus in atopic asthma. *Thorax* **57**, 328-332 (2002).
- 410 19. J. M. Corne *et al.*, Frequency, severity, and duration of rhinovirus infections in asthmatic and
411 non-asthmatic individuals: a longitudinal cohort study. *Lancet* **359**, 831-834 (2002).
- 412 20. J. W. Schoggins *et al.*, A diverse range of gene products are effectors of the type I interferon
413 antiviral response. *Nature* **472**, 481-485 (2011).
- 414 21. S. N. Waggoner *et al.*, Roles of natural killer cells in antiviral immunity. *Curr Opin Virol* **16**, 15-23
415 (2016).

- 416 22. A. Nikonova *et al.*, M1-like macrophages are potent producers of anti-viral interferons and M1-
417 associated marker-positive lung macrophages are decreased during rhinovirus-induced asthma
418 exacerbations. *EBioMedicine* **54**, 102734 (2020).
- 419 23. L. Whitman, H. Zhou, S. Perlman, T. E. Lane, IFN-gamma-mediated suppression of coronavirus
420 replication in glial-committed progenitor cells. *Virology* **384**, 209-215 (2009).
- 421 24. L. Malmgaard, Induction and regulation of IFNs during viral infections. *J Interferon Cytokine Res*
422 **24**, 439-454 (2004).
- 423 25. L. J. Finney *et al.*, Human Rhinovirus Impairs the Innate Immune Response to Bacteria in Alveolar
424 Macrophages in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* **199**, 1496-
425 1507 (2019).
- 426 26. P. Mallia *et al.*, Experimental rhinovirus infection as a human model of chronic obstructive
427 pulmonary disease exacerbation. *Am J Respir Crit Care Med* **183**, 734-742 (2011).
- 428 27. A. Singanayagam *et al.*, Corticosteroid suppression of antiviral immunity increases bacterial
429 loads and mucus production in COPD exacerbations. *Nat Commun* **9**, 2229 (2018).
- 430 28. A. Singanayagam *et al.*, Antiviral immunity is impaired in COPD patients with frequent
431 exacerbations. *Am J Physiol Lung Cell Mol Physiol* **317**, L893-L903 (2019).
- 432 29. R. Thwaites *et al.*, Clinical burden of severe respiratory syncytial virus infection during the first 2
433 years of life in children born between 2000 and 2011 in Scotland. *Eur J Pediatr* **179**, 791-799
434 (2020).
- 435 30. T. Takahashi *et al.*, Sex differences in immune responses that underlie COVID-19 disease
436 outcomes. *Nature* 10.1038/s41586-020-2700-3 (2020).
- 437 31. M. Contoli *et al.*, Role of deficient type III interferon-lambda production in asthma
438 exacerbations. *Nat Med* **12**, 1023-1026 (2006).
- 439 32. N. Yang, H. M. Shen, Targeting the Endocytic Pathway and Autophagy Process as a Novel
440 Therapeutic Strategy in COVID-19. *Int J Biol Sci* **16**, 1724-1731 (2020).
- 441 33. E. Andreakos, I. Zanoni, I. E. Galani, Lambda interferons come to light: dual function cytokines
442 mediating antiviral immunity and damage control. *Curr Opin Immunol* **56**, 67-75 (2019).
- 443 34. I. E. Galani *et al.*, Interferon-lambda Mediates Non-redundant Front-Line Antiviral Protection
444 against Influenza Virus Infection without Compromising Host Fitness. *Immunity* **46**, 875-890
445 e876 (2017).
- 446 35. M. R. Khaitov *et al.*, Respiratory virus induction of alpha-, beta- and lambda-interferons in
447 bronchial epithelial cells and peripheral blood mononuclear cells. *Allergy* **64**, 375-386 (2009).
- 448 36. E. Mantlo, N. Bukreyeva, J. Maruyama, S. Paessler, C. Huang, Antiviral activities of type I
449 interferons to SARS-CoV-2 infection. *Antiviral Res* **179**, 104811 (2020).
- 450 37. U. Felgenhauer *et al.*, Inhibition of SARS-CoV-2 by type I and type III interferons. *J Biol Chem*
451 10.1074/jbc.AC120.013788 (2020).
- 452 38. I. F. Hung *et al.*, Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the
453 treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2
454 trial. *Lancet* 10.1016/S0140-6736(20)31042-4 (2020).
- 455 39. S. Shalhoub, Interferon beta-1b for COVID-19. *Lancet* 10.1016/S0140-6736(20)31101-6 (2020).
- 456 40. V. Gielen, S. L. Johnston, M. R. Edwards, Azithromycin induces anti-viral responses in bronchial
457 epithelial cells. *Eur Respir J* **36**, 646-654 (2010).
- 458 41. M. Menzel, H. Akbarshahi, L. Bjermer, L. Uller, Azithromycin induces anti-viral effects in cultured
459 bronchial epithelial cells from COPD patients. *Sci Rep* **6**, 28698 (2016).
- 460 42. M. Menzel *et al.*, Azithromycin augments rhinovirus-induced IFNbeta via cytosolic MDA5 in
461 experimental models of asthma exacerbation. *Oncotarget* **8**, 31601-31611 (2017).

- 462 43. J. D. Porter *et al.*, Identification of novel macrolides with antibacterial, anti-inflammatory and
463 type I and III IFN-augmenting activity in airway epithelium. *J Antimicrob Chemother* **71**, 2767-
464 2781 (2016).
- 465 44. F. Touret *et al.*, *In vitro* screening of a FDA approved chemical library reveals
466 potential inhibitors of SARS-CoV-2 replication. 10.1101/2020.04.03.023846 %J bioRxiv,
467 2020.2004.2003.023846 (2020).
- 468 45. L. B. Bacharier *et al.*, Early Administration of Azithromycin and Prevention of Severe Lower
469 Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized
470 Clinical Trial. *JAMA* **314**, 2034-2044 (2015).
- 471 46. P. G. Gibson *et al.*, Effect of azithromycin on asthma exacerbations and quality of life in adults
472 with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled
473 trial. *Lancet* **390**, 659-668 (2017).
- 474 47. P. Holt, D. Strickland, A. Custovic, Targeting maternal immune function during pregnancy for
475 asthma prevention in offspring: harnessing the "farm effect"? *J Allergy Clin Immunol*
476 10.1016/j.jaci.2020.04.008 (2020).
- 477 48. J. P. Collet *et al.*, Effects of an immunostimulating agent on acute exacerbations and
478 hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study
479 Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an
480 Immunostimulant. *Am J Respir Crit Care Med* **156**, 1719-1724 (1997).
- 481 49. B. Orcel, B. Delclaux, M. Baud, J. P. Derenne, Oral immunization with bacterial extracts for
482 protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis.
483 *Eur Respir J* **7**, 446-452 (1994).
- 484 50. S. Esposito *et al.*, A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial
485 to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract
486 infections. *J Transl Med* **17**, 284 (2019).
- 487 51. I. Iheanacho, Take it like a man: pseudodrugs for man flu. *BMJ* **342**, d2863 (2011).
- 488 52. A. Custovic *et al.*, The National Asthma Campaign Manchester Asthma and Allergy Study. *Pediatr*
489 *Allergy Immunol* **13**, 32-37 (2002).
- 490 53. A. Custovic *et al.*, Cytokine Responses to Rhinovirus and Development of Asthma, Allergic
491 Sensitization, and Respiratory Infections during Childhood. *Am J Respir Crit Care Med* **197**, 1265-
492 1274 (2018).
- 493 54. A. Semic-Jusufagic *et al.*, Assessing the association of early life antibiotic prescription with
494 asthma exacerbations, impaired antiviral immunity, and genetic variants in 17q21: a population-
495 based birth cohort study. *Lancet Respir Med* **2**, 621-630 (2014).
- 496 55. Y. Benjamini, Y. Hochberg, Controlling the False Discovery Rate: A Practical and Powerful
497 Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B (Methodological)*
498 **57**, 289-300 (1995).

499

500 **Figures and Tables**




501

502 **Fig. 1: Participant flow and PBMC stimulation numbers for each stimulus.**

503

504

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



505


506 **Figure 2. Patterns of PBMC cytokine induction by viral stimuli, compared to medium controls.**

507 Data were analysed using Wilcoxon test. Each dot represents an individual participant. Box plots
508 represent the 25th and 75th percentiles, the line the median, with whiskers at the 10th and 90th percentiles.

509 Data are presented in pg/mL. The y axis is plotted on a logarithmic scale. Significant levels: *** $P < 0.001$

510 compared to medium.

511




512

513 **Figure 3: Females have significantly greater induction than males of type I and II IFNs and**
514 **CXCL10/IP-10 in response to RV-A16.**

515 Box plots represent the 25th and 75th percentiles, the line the median, with whiskers at the 10th and 90th
516 percentiles. Each dot represents an individual participant. Wilcoxon test: A) $P < 0.001$, B) $P < 0.001$, C)
517 $P = 0.003$ and D) $P = 0.010$. Data are presented as fold induction. The y axis is plotted on a logarithmic scale.

518




519

520 **Figure 4: Females have significantly greater induction than males of type I and II IFNs and**
521 **CCL13/MCP4 in response to the viral mimics R848 and CpG-A.**

522 Box plots represent the 25th and 75th percentiles, the line the median, with whiskers at the 10th and 90th
523 percentiles. Each dot represents an individual participant. Wilcoxon test: A) $P < 0.001$, B) $P = 0.015$, C)
524 $P = 0.003$ and D) $P = 0.040$. Data are presented as fold induction. The y axis is plotted on a logarithmic
525 scale.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



526

527 **Figure 5: Proportions of males and females with IFN responses to RV-A16, RSV and R848 below**
528 **the 15th, 20th and 25th percentiles of the entire population.**

529 *P*-values are derived using chi-squared tests.

530 **Table 1: Comparison between sexes of demographic and clinical characteristics of the study**
 531 **population.**

532 Some data was lost due to individuals not attending a follow up or skipping the question

	Cytokine data (n=345)		
	Female	Male	p-value
	n (%)	n (%)	χ^2
Ethnicity (Caucasian)	121/126(96.0)	204/212(96.2)	0.504
Younger siblings	112/217(51.6)	70/128(54.7)	0.581
Older siblings	62/128 (48.4)	121/215 (56.3)	0.159
Day care attendance	91/121(75.2)	153/209(73.2)	0.690
Maternal smoking (pregnancy)	9/128 (7.0)	19/212 (9.0)	0.530
Maternal smoking (current)	10/126(7.9)	29/217(13.4)	0.127
Maternal asthma	23/128 (18.0)	39/217 (18.0)	0.999
Paternal asthma	22/128 (17.2)	29/217 (13.4)	0.334
Dog ownership	40/127(31.5)	80/216(37.0)	0.298
Cat ownership	29/127(22.8)	54/215(25.1)	0.634
Current asthma	20/126 (18.3)	39/213 (18.3)	0.567
Current wheeze	18/126(14.3)	33/215 (15.3)	0.790
	Mean(SD)	Mean(SD)	t-test
Age at follow up	16.0 (0.65)	16.1 (0.55)	0.763
Birth weight (kg)	3.42 (0.47)	3.51(0.91)	0.242

533

534 .

535 **Table 2: Differences between males and females in IFN and IFN-induced chemokine responses to**
 536 **viral stimuli.** Data were analysed using the Wilcoxon test. *P* values and adjusted *P* values less than 0.05
 537 are in bold. The group with the higher IFN and IFN-induced chemokine induction is highlighted in grey.

Stimulus	Cytokine	Median log2 fold Induction [IQR]	Median log2 fold Induction [IQR]	Female to Male ratio in fold induction	<i>P</i> value	Adjusted <i>P</i> value
RV-A16		Female, n=128 (37.2%)	Male, n=216 (62.8%)			
	IFN- α	10.24 [8.98-11.55]	9.30 [7.88-10.53]	1.92	<0.001	0.001
	IFN- β	6.01 [4.66-7.26]	4.98 [2.02-6.66]	2.04	<0.001	0.003
	IFN- γ	7.69 [6.04-8.90]	6.87 [5.03-8.15]	1.77	0.003	0.017
	CCL4/MIP-1 β	2.13 [1.47-3.25]	1.98 [0.96-2.98]	1.11	0.125	0.231
	CXCL10/IP-10	4.15 [3.13-5.27]	3.66 [2.36-4.95]	1.04	0.010	0.041
	CCL13/MCP4	2.60 [1.19-3.85]	2.10 [0.93-3.41]	1.41	0.076	0.149
	CCL2/MCP1	2.09 [1.09-2.95]	1.91 [0.95-2.92]	1.13	0.659	0.721
RSV		Female n=128 (37.1%)	Male n=217 (62.9%)			
	IFN- α	11.66 [10.53-12.53]	11.24 [9.91-12.21]	1.34	0.018	0.055
	IFN- β	6.89 [5.83-7.49]	6.62 [5.58-7.71]	1.21	0.583	0.658
	IFN- γ	7.08 [5.88-8.14]	6.54 [4.84-8.11]	1.45	0.062	0.142
	CCL4/MIP-1 β	1.60 [1.08-2.36]	1.58 [0.98-2.20]	1.01	0.380	0.475
	CXCL10/IP-10	3.67 [2.59-4.83]	3.36 [2.38-4.62]	1.24	0.210	0.304
	CCL13/MCP4	1.46 [0.42-2.51]	1.12 [-0.11-2.13]	1.27	0.019	0.055
	CCL2/MCP1	1.75 [0.93-2.53]	1.64 [0.64-2.65]	1.08	0.799	0.848
RV-A1		Female n=115 (37.2%)	Male n=194 (62.8%)			
	IFN- α	7.54 [5.68-8.92]	6.91 [4.92-8.34]	1.55	0.011	0.041
	IFN- β	1.21 [1.21-3.61]	1.21 [1.21-3.16]	1.00	0.483	0.583
	IFN- γ	6.08 [4.32-7.27]	5.51 [3.69-6.83]	1.48	0.066	0.142
	CCL4/MIP-1 β	0.93 [0.43-1.41]	0.71 [0.20-1.13]	1.16	0.010	0.041
	CXCL10/IP-10	3.05 [1.94-4.17]	2.75 [1.36-3.85]	1.23	0.041	0.104
	CCL13/MCP4	3.39 [2.07-4.47]	2.70 [0.67-3.80]	1.61	0.002	0.017
	CCL2/MCP1	2.00 [1.09-2.77]	1.84 [0.85-2.58]	1.12	0.217	0.304
R848		Female n=102 (37.6%)	Male n=169 (62.4%)			
	IFN- α	9.91 [8.41-11.52]	8.87 [7.47-10.26]	2.06	<0.001	0.002
	IFN- β	1.53 [1.53-3.27]	1.53 [1.53-2.84]	1.00	0.158	0.261
	IFN- γ	7.51 [5.84-9.14]	7.11 [5.45-8.60]	1.32	0.164	0.261
	CCL4/MIP-1 β	3.58 [2.94-4.45]	3.46 [2.56-4.42]	1.09	0.375	0.475
	CXCL10/IP-10	2.15 [1.25-3.15]	1.79 [1.04-2.82]	1.28	0.069	0.142
	CCL13/MCP4	0.83 [-0.31-1.85]	0.76 [-0.85-1.69]	1.05	0.239	0.322
	CCL2/MCP1	2.26 [0.79-3.14]	2.02 [0.97-3.04]	1.18	0.914	0.914
CpG-A		Female n=91 (36.9%)	Male n=156 (63.1%)			
	IFN- α	12.6 [10.99-13.73]	11.83 [10.47-13.38]	1.71	0.015	0.051
	IFN- β	6.31 [2.86-8.10]	5.71 [1.40-7.56]	1.52	0.155	0.261
	IFN- γ	4.04 [2.29-5.17]	3.03 [1.54-4.26]	2.01	0.003	0.017
	CCL4/MIP-1 β	1.35 [0.91-1.91]	1.43 [0.87-1.81]	0.95	0.857	0.882
	CXCL10/IP-10	4.02 [2.94-4.93]	3.66 [2.71-4.67]	1.28	0.204	0.304
	CCL13/MCP4	2.56 [1.70-3.53]	2.12 [0.88-3.32]	1.36	0.040	0.104
	CCL2/MCP1	1.66 [1.07-2.19]	1.54 [0.89-2.07]	1.09	0.528	0.616